RecruitingNCT06283316
Systemic Treatments for Alopecia Areata Registry
Sponsor
Erasmus Medical Center
Enrollment
10,000 participants
Start Date
Jan 17, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
A multicenter prospective registry (STA2R) is conducted to assess systemic treatments for alopecia areata, focusing on effectiveness, safety, and long-term outcomes.
Eligibility
Min Age: 16 Years
Inclusion Criteria3
- Diagnosed with alopecia areata;
- Starting/using a systemic treatment for alopecia areata;
- Informed consent for registry participation obtained from patient and/or caretaker.
Exclusion Criteria2
- Not sufficiently capable of understanding the Dutch language;
- Not willing to participate.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06283316
Related Trials
Deciphering the Genetic Architecture of Autoimmune Diseases
NCT069481102 locations
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
NCT075072011 location
Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
NCT057890301 location
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases
NCT067471563 locations
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases
NCT0634271313 locations